Adding Cannabis Substitution to a Managed Alcohol Program: An Operational Guide
Last Updated: February 2026 | Reading Time: 6 minutes | Audience: Program directors, clinical leads, harm reduction coordinators
Cannabis substitution — providing regulated cannabis to MAP participants to support reduction in alcohol consumption — has moved from pilot concept to peer-reviewed evidence. The question for program directors is no longer whether it works, but how to implement it within an existing program. This guide covers the operational steps: what cannabis substitution requires, how the supply chain works, and where it fits within the broader MAP framework.
For the evidence base, see: Cannabis in Managed Alcohol Programs: Evidence and Implementation Considerations. For the full MAP operational framework, see the BCCSU/CISUR Managed Alcohol Programs: Canadian Operational Guidance (2023), which was developed by the same research institution that independently evaluated the CMAPS pilots.
What Cannabis Substitution Adds to a MAP
A MAP already provides regulated alcohol, health services, peer support, and case management. Cannabis substitution adds a regulated cannabis option — distributed through a Health Canada licensed seller — alongside the existing alcohol management plan. Participants who choose to use cannabis do so in addition to or instead of their managed alcohol doses, based on individual preference and clinical guidance.
The substitution effect documented in the Ottawa CMAPS pilot operated through stable individual patterns established over time, not acute day-to-day trade-offs. This means the program design goal is consistent, reliable access to a regulated supply — not a tightly managed exchange protocol. The Vancouver CMAPS pilot, operated by High Hopes Research Society, found that introducing a regulated cannabis supply reduced grey-market cannabis use among participants, meaning the program redirected existing behaviour rather than introducing new substance use.
Cannabis substitution does not replace the alcohol management component of the MAP. It adds a harm reduction option for participants who want it.
Step 1: Assess Participant Readiness and Interest
The CMAPS feasibility study (Pauly et al., 2021) found that over 63% of MAP participants were already using cannabis to substitute for alcohol informally at baseline. For most programs, a significant portion of the potential participant pool is already doing this — without a regulated supply or clinical support.
A pre-implementation needs assessment should determine: what proportion of current MAP participants are already using cannabis; what formats they prefer; and whether they have existing licensed seller registrations or are purchasing through grey-market sources. This information shapes supply planning and helps prioritize which participants to enrol first.
Peer workers embedded in your program are the most effective mechanism for this assessment. The Bailey et al. (2023) co-design process documented in CMAPS demonstrates that lived-experience input at this stage significantly improves program design and participant uptake.
Step 2: Identify Your Supply Model
Cannabis substitution requires a Health Canada-licensed seller. Under the Cannabis Regulations, a licensed seller registered under Part 14 can supply registered patients directly. For MAP settings, two supply models are possible:
Direct patient registration: Each participating MAP client is individually registered with the licensed seller, using the program’s address as their shipping address under s. 279 of the Cannabis Regulations. The licensed seller ships directly to the program address. The program manager signs a brief attestation confirming that the facility provides social services to the participant. The licensed seller holds the compliance obligations.
Institutional supply agreement: For programs that operate as or within provincially licensed healthcare facilities, a direct supply agreement with the licensed seller may be appropriate. The compliance structure differs — see Healthcare Cannabis Storage Protocols: Regulatory Requirements and Best Practices for the applicable framework.
For most MAP settings, direct patient registration is the operationally lighter model. The program does not purchase cannabis in bulk, does not hold inventory compliance obligations, and does not require a cannabis licence. The licensed seller manages registration, supply, and regulatory reporting.
High Hopes Research Society, the organization under which Flora Initiative operates, has direct operational experience with the direct patient registration model in a MAP setting, documented in the CMAPS research program. Contact our institutional team to discuss supply arrangements.
Step 3: Establish Your Distribution Protocol
The CMAPS Ottawa pilot used a one pre-rolled joint per managed alcohol dose protocol, distributed by peer researchers. This is one approach — programs should design their distribution protocol based on participant needs, staffing model, and clinical guidance available.
Key decisions for your protocol:
Who distributes: The CMAPS research supports peer-researcher involvement in distribution as both clinically appropriate and operationally effective. Peer staff who are trusted by participants and understand the program context are well-positioned for this role. Clinical oversight for initial assessment and plan development is recommended; day-to-day distribution can be led by trained non-clinical staff.
When and how often: Consistent access matters more than precise scheduling. Whether you structure distribution at fixed times, on-demand during staffed hours, or tied to alcohol dose schedules, the goal is reliable availability. Participants who know cannabis is consistently accessible are more likely to use it as a planned alternative rather than supplementing with grey-market supply.
Format: The Ottawa pilot used pre-rolled joints (approximately 16–22% THC). Other formats — oils, capsules, dried flower for self-rolling — may be appropriate depending on your participant population’s preferences and your distribution infrastructure. Your licensed seller can provide multiple formats under a single registration.
Documentation: Maintain a dispensing log that tracks the quantities provided to each registered participant. This supports both program evaluation and compliance with any funder documentation requirements.
Step 4: Address the Medical Authorization
Each participating MAP client needs a valid medical authorization document from a licensed healthcare practitioner. This is the legal basis for their registration with the licensed seller. For MAP populations, accessing a practitioner willing to authorize cannabis can be a barrier — particularly for participants without a family physician.
Some licensed sellers, including Flora, can connect MAP participants with clinical assessment services from practitioners with specific experience in this population and context. Flora’s clinical assessments are conducted by the team behind the peer-reviewed CMAPS research — the same practitioners who developed the medical framework for the programs the evidence is based on.
The medical authorization specifies a daily gram quantity and a period of use up to one year. For MAP populations with complex health histories, practitioners experienced with this population will have relevant context for authorization decisions that general practitioners may lack.
Step 5: Integrate with Your Existing Program Infrastructure
Cannabis substitution fits within your existing harm reduction framework rather than requiring a parallel structure. Practical integration points:
Intake and consent: Add cannabis substitution as an option within your standard intake process. Participation is voluntary and should be documented as such. Informed consent should cover the nature of the cannabis supply, the registration process with the licensed seller, and the participant’s right to withdraw.
Individual plans: Existing alcohol management plans (AMPs) can note cannabis substitution as an additional harm reduction strategy. The CMAPS evidence suggests the substitution effect develops over time through individual patterns — AMPs should reflect this as an ongoing preference rather than a fixed protocol.
Monitoring: Standard MAP monitoring practices — sick cups dispensed, hospital visits, alcohol consumption observations — are the appropriate outcome measures for cannabis substitution evaluation. The CMAPS Vancouver analysis used sick cups as the primary indicator of withdrawal severity reduction. Your program’s existing monitoring data provides a pre-implementation baseline.
Peer roles: If peer workers are already embedded in your MAP, expanding their role to include cannabis distribution and harm reduction education is a natural extension. The Bailey et al. (2023) knowledge translation work documented in CMAPS describes the co-design of educational resources for exactly this context.
Funding and Cost Structure
Under the direct patient registration model, cannabis costs are borne by the individual patient’s coverage or by the patient directly — not by the MAP’s program budget. For participants without coverage, some programs access provincial or municipal harm reduction funding to subsidize cannabis access. The CMAPS pilots were supported through Health Canada’s Substance Use and Addictions Program (SUAP) funding, which remains an available funding pathway for harm reduction programs adding evidence-based interventions.
For participants eligible under IFHP, VAC, or other Medavie Blue Cross programs, direct billing through a registered licensed seller eliminates out-of-pocket cost entirely.
Evaluation
The BCCSU/CISUR MAP operational guidance recommends building evaluation into MAP design from the start. For cannabis substitution specifically, the CMAPS research provides both a validated methodological approach (hierarchical mixed-effects modelling with between-person and within-person effects) and practical outcome indicators suitable for program-level monitoring without academic research infrastructure.
At minimum, track: cannabis dispensed by participant per week; sick cups dispensed per participant per week; self-reported alcohol consumption at intake and regular intervals; and any adverse events. These data support both internal program improvement and funder reporting, and create the foundation for contributing to the growing evidence base if your program chooses to pursue formal evaluation.
High Hopes Research Society and Flora Initiative are available as research partners for programs evaluating cannabis substitution outcomes.
References
- Bailey, Harps, Belcher, Williams, Amos, Graham, Goulet-Stock et al. (2023). International Journal of Drug Policy. DOI: 10.1016/j.drugpo.2023.102918
- BCCSU and CISUR. (2023). Managed Alcohol Programs: Canadian Operational Guidance Document. Vancouver: BCCSU.
- Goulet-Stock, Hacksel, Scandiuzzi, Boyd, Pauly & Stockwell (2026). International Journal of Drug Policy, 147: 105083. DOI: 10.1016/j.drugpo.2025.105083
- Pauly, Brown, Chow, Wettlaufer, Graham, Urbanoski et al. (2021). Harm Reduction Journal, 18: 65. DOI: 10.1186/s12954-021-00512-5